We’re working to invent a world where cancer isn’t just treated, but cured.
Our mission is to deliver breakthrough innovations that extend and improve the lives of people with cancer
We work to prevent cancer through preventive vaccination and to provide oncologists with treatment options that give their patients a better quality of life and more time.
Everyone knows someone who has been touched by cancer. When a cancer diagnosis happens, what matters most isn’t what the next scientific breakthrough is – but when it will be available to patients in Switzerland.
Our work in oncology
clinical trials involving our cancer medicines in Switzerland (as of 07/2022).
patients currently enrolled in our clinical trials in Switzerland and about 200 patients are actively on study drug (as of 07/2022).
different types of cancer are being studied in our clinical trials Switzerland (as of 07/2022).
Our company has a long history of bringing forward innovative medicines. In the field of oncology, we focus on immunotherapy, which aims to activate the body's own immune system to fight the tumor. Our relentless commitment to research and development has enabled us to establish an exceptionally broad research program with around 1'600 studies. Switzerland is part of this program, currently conducting 29 clinical trials in 12 different tumor types (as of 07/2022). Today, our portfolio includes oncology medicines that treat different cancers and conditions related to cancer treatment.
Access to care
Improving access to cancer care is our strategic priority. We are working with the entire cancer community to help patients gain access to the oncology medicines that they need and to expand the provision of quality cancer care.
The Swiss Oncology team is
- collaborating with authorities and institutions to ensure access to our medicines
- working on solutions how to continuously improve the support of healthcare professionals and patients in the treatment of cancer
- interacting with Oncologists, Scientific leaders and patient organizations to gain insight into market and customer needs.
Progress through partnerships
We work with the entire cancer community - advocacy partners, health care providers, government and industry colleagues - all who share our mission to extend and improve the lives of people with cancer.
Our team has engaged in collaborative efforts to raise the awareness of cancer and improve its prevention, including the creation of regular platforms for stakeholder to advance health policy discussions around cancer care. Furthermore we are a founding member of the multi-stakeholder alliance “All.Can” which aims to exploit efficiency in cancer care.
We participate in several initiatives to support patients with cancer. These include:
- a website for disease management
- campaigns to educate the public about early signs and detection
- a partnership to improve sustainable cancer care all-can.org.
Key therapeutic areas
MSD is one of the world 's leading companies in oncology. Visionary research and collaborative action have already led to breakthroughs for the prevention and treatment of certain types of cancer and we're committed to driving further innovation to help change the future of this disease.
Business Unit Director Oncology · MSD Switzerland
It takes all of us to beat cancer
We’re continuing to accelerate what we can achieve for patients, to offer them more options for treating their cancer and, hopefully, more time. Discover more about what we do to beat cancer.
Survey on cancer care in Switzerland: Good ratings—But some work to do
Cancers pose a major challenge not only for those affected but also for the health care system. MSD has worked with the research institute gfs.bern to create a representative survey, the first of its kind, to take a detailed look at public opinion regarding the quality of cancer care in Switzerland. The survey showed that […]
Things to know about cancer and the biomarker MSI-H/dMMR
Cancer patients need treatment that is most suitable for their specific disease. Biomarkers, biological characteristics that can be measured in blood or tissue samples, are an aid in finding the right treatment. MSI-h/dMMR is such a biomarker.
What we do to support Lung Cancer Awareness Month
November is Lung Cancer Awareness Month. A month dedicated to those affected and to raising public awareness about the causes, early detection and prevention of the disease. Did you know lung cancer is the leading cause of cancer death worldwide? At MSD, we are committed to fighting lung cancer and improving cancer care. Learn how we support Lung Cancer Awareness Month.